World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00615381
Date of registration: 21/01/2008
Primary sponsor: Northwestern University
Public title: Supraphysiologic Insulin to Improve Outcomes After Surgical Treatment of Unruptured Cerebral Aneurysms
Scientific title: Clinical Trial of Euglycemia Maintenance With Supraphysiologic Insulin vs Conventional Intensive Insulin Therapy to Improve Outcomes (Neurologic, Neuropsychiatric, and Biomarkers) After Surgical Treatment of Unruptured Cerebral Aneurysms
Date of first enrolment: January 2009
Target sample size: 300
Recruitment status: Withdrawn
URL:  http://clinicaltrials.gov/show/NCT00615381
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Countries of recruitment
United States
Contacts
Name:   Dhanesh K. Gupta, M.D.
Address: 
Telephone:
Email:
Affiliation:  Northwestern University Feinberg School of Medicine
Key inclusion & exclusion criteria

Inclusion Criteria:

- Unruptured intracranial aneurysm

Exclusion Criteria:

- Diabetes

- Pregnancy

- Age less than 18 years

- Inability to undergo preoperative neuropsychiatric and neurologic functional testing



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Intracranial Aneurysm
Intervention(s)
Drug: Novolin R (Human Recombinant Insulin)
Primary Outcome(s)
Neurologic Outcome--"poor" vs. "good." A "poor" outcome is assigned if the patient who arrived independently from home is discharged to a nursing home or rehabilitation hospital or dies. [Time Frame: Discharge from hospital after surgery]
Secondary Outcome(s)
Amount of time blood glucose concentration is outside the target glucose concentration range (80-120 mg/dL) [Time Frame: Perioperative Period (Induction of anesthesia + 24 hrs)]
Biomarkers of the Perioperative Inflammatory Response [Time Frame: Perioperative Period (Induction of anesthesia + 48 hrs)]
Neurologic Status (Glasgow Outcome Scale <=4; Modified Rankin Disability Scale >=2, NIH Stroke Scale <=10) [Time Frame: Postoperative day 7, 90+/- 14 days, and 365+/-30 days]
Neuropsychiatric outcomes [Time Frame: Postoperative day 7, 90+/- 14 days, and 365+/-30 days]
Secondary ID(s)
DKG 2498-002
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history